Rodríguez-Gil MA, García Boyero R, de Miguel Llorente D, Olave Rubio MT, Domínguez-Hernández R, Pardo C, Martín-Escudero V, Redondo Izal AM 7
The economic benefit for patients and caregivers of expanding CAR-T centres in Spain
EBMT 52nd Annual Meeting. Madrid. 22-25 mar 2026
Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Vadgama S, Casado MÁ, Pardo C
The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain
Cancers. https://doi.org/10.3390/cancers16152712
García-Sancho AM, Presa M, Pardo C, Martín-Escudero V, Oyagüez I, Ortiz-Maldonado V
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain
Cancers 2024, 16, 2301
Peral C, De Lossada A, Lwoff N, Espinoza-Cámac N, Casado MA, Burke T, Alvir J, Thakkar S, Ferri-Grazzi E
Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence insights from the CHESS II Study
JHEOR. 2024;11(1):122-133
Aguado JM, Navarro D, Montoto C, Yébenes M, de Castro-Orós I
Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review
Transplantation Reviews. doi: 10.1016/j.trre.2023.100804
MÁS INFORMACIÓN
Martín A, Presa M, Tejado N, Pardo C, Martín-Escudero V, Oyagüez I, Ortiz-Maldonado V
Eficiencia de axicabtagén ciloleucel en el tratamiento en segunda línea del linfoma B difuso de células grandes en España
LXV Congreso Nacional de la SEHH, XXXIX Congreso Nacional de la SETH y III Congreso Iberoamericano de Hematología. Sevilla. 26-28 oct 2023
Ortiz-Maldonado V, Presa M, Tejado N, Pardo C, Martín-Escudero V, Oyagüez I, Martín A
Axicabtagene Ciloleucel As Second-Line Treatment For Relapsed/ Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis Refractory Large B-Cell Lymphoma In Spain: A Cost-Effectiveness Analysis
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
Peral C, de Lossada Juste A, Lwoff N, Espinoza Cámac N, Martínez-Martínez N, Casado MÁ, Burke T, Kane A, Alvir J, Thakkar S, Ferri Grazzi E
Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study
26th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 12-15 nov 2023
Álvarez-Román MT, Berrueco R, Haya S, Moretó A, R. López M, Mareque M, Casado MA, ConsensuHemos working group
Delphi consensus on managing prophylactic treatment in patients with severe hemophilia A in Spain
Sangre. 2023;42(1)
MÁS INFORMACIÓN